PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.47%
R&D growth above 10% signals aggressive investment. Seth Klarman would demand evidence of future payoff potential.
-1.59%
Negative G&A growth (overhead reduction) needs verification. Benjamin Graham would examine impact on operations.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
14.64%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
14.64%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
8.11%
D&A growth 5-10% suggests significant asset additions. Howard Marks would investigate investment returns.
-14.78%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-14.64%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-24.66%
Negative other expenses growth needs verification. Benjamin Graham would examine sustainability.
-15.16%
Negative pre-tax income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
14.88%
Tax expense growth 10-20% suggests significant increase. Howard Marks would demand explanation.
-15.16%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
2.78%
EPS growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
2.78%
Diluted EPS growth 0-4% indicates modest gains. Howard Marks would investigate growth potential.
19.07%
Share increase above 2% signals significant dilution. Seth Klarman would demand explanation.
19.07%
Diluted share increase above 2% signals significant dilution. Seth Klarman would demand explanation.